Drug Trial Radar · NCT07869043
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Jun 7, 2029
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.
Conditions
- Asthma
Interventions
tilrekimigDrug
subcutaneous injection
PlaceboOther
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized asthma exacerbation rate over 52 weeksTime frame: Baseline through Week 52
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Asthma and Allergy Center of Chicago
River Forest, Illinois · Recruiting
Hannibal Regional Healthcare System, Inc.
Hannibal, Missouri · Not yet recruiting
Urban Health Plan
The Bronx, New York · Not yet recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Not yet recruiting
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania · Recruiting
Orion Clinical Research
Austin, Texas · Recruiting
Southwest Medical Center (Building I) aka Southwest Family Medicine Associates
Dallas, Texas · Not yet recruiting
A & A Research Consultants, LLC
Edinburg, Texas · Not yet recruiting
Western Sky Medical Research
El Paso, Texas · Not yet recruiting
Pulmonary and Sleep Center of the Valley
McAllen, Texas · Not yet recruiting
DM Clinical Research
Tomball, Texas · Recruiting
Solace Clinical Research
Bayamón, Puerto Rico · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.